Sign In
Buy CPRX
$31.49
+0 (+0%)
At Close: Jul 31, 2026
Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst
05:06am, Thursday, 16'th Jul 2026
Angelini Pharma said on Thursday it had completed the acquisition of U.S. rare-disease drug maker Catalyst Pharmaceuticals in a $4.1 billion deal involving Italian state lender CDP.
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals
03:36am, Thursday, 16'th Jul 2026
The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare Diseases Completion of the transaction gives Angelini Pharma ownership o
Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger
06:03am, Friday, 10'th Jul 2026
Catalyst Pharmaceuticals NASDAQ: CPRX stockholders approved the company's proposed merger with Angelini Pharma S.p.A. at a special meeting held virtually on July 8, according to remarks from company o
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data
10:36am, Thursday, 02'nd Jul 2026
Catalyst Pharmaceuticals' Agamree matches Emflaza's glucocorticoid activity while showing less immunosuppression, supporting potential expansion into new rare disease indications.
Data Demonstrate Vamorolone's Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity and Without Evidence of Significant Immunosuppressive Activity at Clinical Doses Data Demonstrate V
Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders?
01:00pm, Thursday, 25'th Jun 2026
Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propo
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
Catalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue?
12:31pm, Wednesday, 10'th Jun 2026
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
10:50am, Wednesday, 27'th May 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
10:41am, Monday, 25'th May 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CPRX or UTHR: Which Is the Better Value Stock Right Now?
12:41pm, Thursday, 14'th May 2026
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two stocks presents inve
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
12:20pm, Tuesday, 12'th May 2026
CPRX beats Q1 estimates driven by rising Firdapse and Agamree sales amid Angelini Pharma's pending $4.1B acquisition deal.
Are CPRX, UNF, RMAX, ACR Obtaining Fair Deals for their Shareholders?
02:56am, Tuesday, 12'th May 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Catalyst (CPRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
07:30pm, Monday, 11'th May 2026
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimat
